Drug Profile
MK 2640
Alternative Names: MK-2640Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (IV, Infusion)
- 01 Jul 2016 Merck completes a phase I trial for Type-1 diabetes mellitus in USA (NCT02269735)
- 01 Nov 2014 Phase-I clinical trials in Type-1 diabetes mellitus in USA (IV)